Better Choice Company Inc. - BTTR STOCK NEWS

Better Choice Company (BTTR) announces plans to monetize its R&D platform after acquiring Aimia. The company aims to develop a treat-based GLP1 supplement to combat obesity in pets.

Better Choice Company (BTTR) acquires Aimia Pet Healthco Inc. to develop weight loss supplements for pets, aiming to combat obesity-related health issues in domestic animals.

Better Choice Company (NYSE: BTTR) announced a memorandum of understanding (MOU) signed by Aimia Pet HealthCo. Inc. with KGK Science Inc. for the development of a GLP1 supplement for pets. The MOU outlines KGK's research and development of a GLP1 supplement for use in companion animals, aiming to address obesity and other health issues in overweight pets. KGK is a leading Canadian research organization with expertise in clinical trials and regulatory support. Better Choice sees this as a significant opportunity for the pet health industry and is working to become a pioneer in this sector.

Better Choice Company, Inc. (BTTR) announced its Q3 2023 results, revealing an 11% YOY revenue growth to $13.1 million. Adjusted EBITDA soared by 95% YOY, and EPS grew by 77% YOY. The company's financial highlights, operational update, and future outlook were also provided in the PR.

Better Choice Company (NYSE: BTTR) and Aimia Pet HealthCo Inc. (APH) announced a memorandum of understanding with Dr. Nadia Crosignani for the development of a GLP1 supplement for pets. This supplement will be used in combination with Better Choices’ Halo branded toppers or treats for dogs and cats to address pet obesity and associated health issues, tapping into a market with over half of dogs and cats globally classified as overweight or obese.

Better Choice Company partners with Aimia Pet Health to develop GLP1 supplement for overweight pets

Better Choice Company received a Notice from NYSE American stating non-compliance with listing standards. The Company must effect a reverse stock split or demonstrate sustained price improvement by March 21, 2024. The stock will continue to trade but with an added designation. The Company is actively engaged in discussions to regain compliance.

Better Choice Company Inc. is evaluating the marketability of its Bona Vida CBD treats and toppers. CAGR expected to be 30%+ through 2030 and regulatory environment improving for CBD based products.

Better Choice Company, Inc. announces Q2 2023 results with 33% growth in EPS YoY and gross margin growth of 543 basis points YoY. Net revenue increased 14% from Q1 2023 to $10.6 million. Operating loss improved 39% YoY to $(2.6) million. The company appointed Kent Cunningham as CEO and entered into a strategic partnership with Alphia, Inc. The supply chain constraints impacted net sales growth, but the largest pet specialty customer realized 55% revenue growth YoY. The company expects the supply chain constraints to be resolved by the end of Q3 2023. The transition to Alphia will improve order fulfillment and gross margins. The company experienced delays in foreign market registrations due to the transition. Despite the challenges, the company is focused on improving operations and financial controls to drive profitability and future growth.